COVID-19 in cancer patients

Trans R Soc Trop Med Hyg. 2022 Sep 10;116(9):767-797. doi: 10.1093/trstmh/trac015.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has currently affected >220 million individuals worldwide. The complex interplay of immune dysfunction, active malignancy, the effect of cancer treatment on the immune system and additional comorbidities associated with cancer and COVID-19 all affect the outcomes of COVID-19 in patients with cancer. We have discussed the published findings (through the end of September 2021) on the effects of cancer on the morbidity and mortality of COVID-19, common factors between cancer and COVID-19, the interaction of cancer and COVID-19 treatments, the impact of COVID-19 on cancer clinical services, immune test findings in cancer patients with COVID-19 and the long-term effects of COVID-19 on cancer survivors.

Keywords: COVID-19; cancer; haematologic malignancies; immunology; outcomes; solid malignancies.

MeSH terms

  • COVID-19*
  • Comorbidity
  • Humans
  • Neoplasms* / complications
  • Neoplasms* / therapy
  • Risk Factors
  • SARS-CoV-2